Involvement of inflammation in Alzheimer's disease pathogenesis and therapeutic potential of anti-inflammatory agents

Archives of Pharmacal Research

Volumn 38, Issue 12, 2015, Pages 2106-2119

  Shadfar, Sina ^a   Hwang, Chul Ju ^b   Lim, Mi Sun ^a   Choi, Dong Young ^a   Hong, Jin Tae ^b  

^a Yeungnam University   (South Korea)

^b Chungbuk National University   (South Korea)

Author keywords

Alzheimer's disease; Amyloidogenesis; Anti inflammatory; Beta amyloid; Neuroinflammation

Indexed keywords

4 O METHYLHONOKIOL; ANTIINFLAMMATORY AGENT; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR AGONIST; MAGNOLIA EXTRACT; MICRORNA; MICRORNA 125B; MICRORNA 146A; MICRORNA 155; MICRORNA 34A; MICRORNA 9; NEUROPROTECTIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OBOVATOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; AUTACOID;

ALZHEIMER DISEASE; ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; ASTROCYTE; BLOOD BRAIN BARRIER; CD4+ T LYMPHOCYTE; CHRONIC STRESS; COGNITION; CYTOKINE RELEASE; DOUBLE BLIND PROCEDURE; GENE DELETION; GENE EXPRESSION; HUMAN; MICROGLIA; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUROTRANSMISSION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHAGOCYTOSIS; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; SYNAPTOGENESIS; T LYMPHOCYTE; TH1 CELL; TH17 CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; PATHOLOGY;

ALZHEIMER DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ASTROCYTES; BRAIN; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MICROGLIA;

EID: 84948712806     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-015-0648-x     Document Type: Review

References (161)

1. Aisen, P.S., K.A. Schafer, M. Grundman, E. Pfeiffer, M. Sano, K.L. Davis, M.R. Farlow, S. Jin, R.G. Thomas, and L.J. Thal. 2003. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial. Journal of the American Medical Association 289: 2819-2826.
2. Alaynick, W.A. 2008. Nuclear receptors, mitochondria and lipid metabolism. Mitochondrion 8: 329-337.
3. Alexandrov, P.N., P. Dua, J.M. Hill, S. Bhattacharjee, Y. Zhao, and W.J. Lukiw. 2012. microRNA (miRNA) speciation in Alzheimer's disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF). International Journal of Biochemistry and Molecular Biology 3: 365-373.
4. Alexandrov, P.N., P. Dua, and W.J. Lukiw. 2014. Up-Regulation of miRNA-146a in progressive, age-related inflammatory neurodegenerative disorders of the human CNS. Frontiers in Neurology 5: 181.
5. Andersen, K., L.J. Launer, A. Ott, A.W. Hoes, M.M. Breteler, and A. Hofman. 1995. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam study. Neurology 45: 1441-1445.
6. Aso, E., and I. Ferrer. 2014. Cannabinoids for treatment of Alzheimer's disease: Moving toward the clinic. Frontiers in Pharmacology 5: 37.
7. Aso, E., S. Juves, R. Maldonado, and I. Ferrer. 2013. CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AbetaPP/PS1 mice. Journal of Alzheimers Disease 35: 847-858.
8. Aso, E., E. Palomer, S. Juves, R. Maldonado, F.J. Munoz, and I. Ferrer. 2012. CB1 agonist ACEA protects neurons and reduces the cognitive impairment of AbetaPP/PS1 mice. Journal of Alzheimer's Disease 30: 439-459.
9. Benzing, W.C., J.R. Wujek, E.K. Ward, D. Shaffer, K.H. Ashe, S.G. Younkin, and K.R. Brunden. 1999. Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. Neurobiology of Aging 20: 581-589.
10. Bhattacharjee, S., Y. Zhao, and W.J. Lukiw. 2014. Deficits in the miRNA-34a-regulated endogenous TREM2 phagocytosis sensor-receptor in Alzheimer's disease (AD); an update. Frontiers in Aging Neuroscience 6: 116.
11. Breitner, J.C., L.D. Baker, T.J. Montine, C.L. Meinert, C.G. Lyketsos, K.H. Ashe, J. Brandt, S. Craft, D.E. Evans, R.C. Green, M.S. Ismail, B.K. Martin, M.J. Mullan, M. Sabbagh, P.N. Tariot, and A.R. Group. 2011. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimer's & Dementia 7: 402-411.
12. Breitner, J.C., B.A. Gau, K.A. Welsh, B.L. Plassman, W.M. McDonald, M.J. Helms, and J.C. Anthony. 1994. Inverse association of anti-inflammatory treatments and Alzheimer's disease: Initial results of a co-twin control study. Neurology 44: 227-232.
13. Browne, T.C., K. McQuillan, R.M. McManus, J.A. O'Reilly, K.H. Mills, and M.A. Lynch. 2013. IFN-gamma Production by amyloid beta-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's disease. The Journal of Immunology 190: 2241-2251.
14. Cabral, G.A., and L. Griffin-Thomas. 2009. Emerging role of the cannabinoid receptor CB2 in immune regulation: Therapeutic prospects for neuroinflammation. Expert Reviews in Molecular Medicine 11: e3.
15. Camacho, I.E., L. Serneels, K. Spittaels, P. Merchiers, D. Dominguez, and B. De Strooper. 2004. Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. Journal of Neuroscience 24: 10908-10917.
16. Carreras, I., A.C. McKee, J.K. Choi, N. Aytan, N.W. Kowall, B.G. Jenkins, and A. Dedeoglu. 2013. R-flurbiprofen improves tau, but not Ass pathology in a triple transgenic model of Alzheimer's disease. Brain Research 1541: 115-127.
17. Casarejos, M.J., J. Perucho, A. Gomez, M.P. Munoz, M. Fernandez-Estevez, O. Sagredo, J. Fernandez Ruiz, M. Guzman, J.G. de Yebenes, and M.A. Mena. 2013. Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. Journal of Alzheimer's Disease 35: 525-539.
18. Choi, D.Y., J.W. Lee, G. Lin, Y.K. Lee, Y.H. Lee, I.S. Choi, S.B. Han, J.K. Jung, Y.H. Kim, K.H. Kim, K.W. Oh, J.T. Hong, and M.S. Lee. 2012a. Obovatol attenuates LPS-induced memory impairments in mice via inhibition of NF-kappaB signaling pathway. Neurochemistry International 60: 68-77.
19. Choi, D.Y., J.W. Lee, J. Peng, Y.J. Lee, J.Y. Han, Y.H. Lee, I.S. Choi, S.B. Han, J.K. Jung, W.S. Lee, S.H. Lee, B.M. Kwon, K.W. Oh, and J.T. Hong. 2012b. Obovatol improves cognitive functions in animal models for Alzheimer's disease. Journal of Neurochemistry 120: 1048-1059.
20. Choi, D.Y., Y.J. Lee, J.T. Hong, and H.J. Lee. 2012c. Antioxidant properties of natural polyphenols and their therapeutic potentials for Alzheimer's disease. Brain Research Bulletin 87: 144-153.
21. Choi, S.H., S. Aid, and F. Bosetti. 2009. The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: Implications for translational research. Trends in Pharmacological Sciences 30: 174-181.
22. Choi, S.H., S. Aid, L. Caracciolo, S.S. Minami, T. Niikura, Y. Matsuoka, R.S. Turner, M.P. Mattson, and F. Bosetti. 2013. Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease. Journal of Neurochemistry 124: 59-68.
23. Chuang, D.Y., M.H. Chan, Y. Zong, W. Sheng, Y. He, J.H. Jiang, A. Simonyi, Z. Gu, K.L. Fritsche, J. Cui, J.C. Lee, W.R. Folk, D.B. Lubahn, A.Y. Sun, and G.Y. Sun. 2013. Magnolia polyphenols attenuate oxidative and inflammatory responses in neurons and microglial cells. Journal of Neuroinflammation 10: 15.
24. Combs, C.K., D.E. Johnson, J.C. Karlo, S.B. Cannady, and G.E. Landreth. 2000. Inflammatory mechanisms in Alzheimer's disease: Inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. Journal of Neuroscience 20: 558-567.
25. Craft, S., B. Cholerton, and L.D. Baker. 2013. Insulin and Alzheimer's disease: Untangling the web. Journal of Alzheimer's Disease 33: S263-S275.
26. Crespo-Biel, N., C. Theunis, and F. Van Leuven. 2012. Protein tau: Prime cause of synaptic and neuronal degeneration in Alzheimer's disease. International Journal of Alzheimer's Disease 2012: 251426.
27. Cudaback, E., N.L. Jorstad, Y. Yang, T.J. Montine, and C.D. Keene. 2014. Therapeutic implications of the prostaglandin pathway in Alzheimer's disease. Biochemical Pharmacology 88: 565-572.
28. Cui, L., Y. Li, G. Ma, Y. Wang, Y. Cai, S. Liu, Y. Chen, J. Li, Y. Xie, G. Liu, B. Zhao, and K. Li. 2014. A functional polymorphism in the promoter region of microRNA-146a is associated with the risk of Alzheimer disease and the rate of cognitive decline in patients. PLoS ONE 9: e89019.
29. Denner, L.A., J. Rodriguez-Rivera, S.J. Haidacher, J.B. Jahrling, J.R. Carmical, C.M. Hernandez, Y. Zhao, R.G. Sadygov, J.M. Starkey, H. Spratt, B.A. Luxon, T.G. Wood, and K.T. Dineley. 2012. Cognitive enhancement with rosiglitazone links the hippocampal PPARgamma and ERK MAPK signaling pathways. Journal of Neuroscience 32: 16725-16735.
30. Du, J., B. Sun, K. Chen, L. Fan, and Z. Wang. 2009. Antagonist of peroxisome proliferator-activated receptor gamma induces cerebellar amyloid-beta levels and motor dysfunction in APP/PS1 transgenic mice. Biochemical and Biophysical Research Communications 384: 357-361.
31. Ekdahl, C.T., Z. Kokaia, and O. Lindvall. 2009. Brain inflammation and adult neurogenesis: the dual role of microglia. Neuroscience 158: 1021-1029.
32. El Khoury, J., M. Toft, S.E. Hickman, T.K. Means, K. Terada, C. Geula, and A.D. Luster. 2007. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nature Medicine 13: 432-438.
33. Esposito, G., C. Scuderi, M. Valenza, G.I. Togna, V. Latina, D. De Filippis, M. Cipriano, M.R. Carratu, T. Iuvone, and L. Steardo. 2011. Cannabidiol reduces Abeta-induced neuroinflammation and promotes hippocampal neurogenesis through PPARgamma involvement. PLoS ONE 6: e28668.
34. Etminan, M., S. Gill, and A. Samii. 2003. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: Systematic review and meta-analysis of observational studies. British Medical Journal 327: 128.
35. Fakhfouri, G., A. Ahmadiani, R. Rahimian, A.A. Grolla, F. Moradi, and A. Haeri. 2012. WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-gamma pathway. Neuropharmacology 63: 653-666.
36. Fisher, Y., A. Nemirovsky, R. Baron, and A. Monsonego. 2010. T cells specifically targeted to amyloid plaques enhance plaque clearance in a mouse model of Alzheimer's disease. PLoS ONE 5: e10830.
37. Frautschy, S.A., and G.M. Cole. 2010. Why pleiotropic interventions are needed for Alzheimer's disease. Molecular Neurobiology 41: 392-409.
38. Fu, Q., J. Hue, and S. Li. 2007. Nonsteroidal anti-inflammatory drugs promote axon regeneration via RhoA inhibition. Journal of Neuroscience 27: 4154-4164.
39. Gabbita, S.P., M.K. Srivastava, P. Eslami, M.F. Johnson, N.K. Kobritz, D. Tweedie, N.H. Greig, F.P. Zemlan, S.P. Sharma, and M.E. Harris-White. 2012. Early intervention with a small molecule inhibitor for tumor necrosis factor-alpha prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's disease. Journal of Neuroinflammation 9: 99.
40. Gasparini, L., E. Ongini, and G. Wenk. 2004. Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: Old and new mechanisms of action. Journal of Neurochemistry 91: 521-536.
41. Geldmacher, D.S., T. Fritsch, M.J. McClendon, and G. Landreth. 2011. A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Archives of Neurology 68: 45-50.
42. Gertsch, J., and S. Anavi-Goffer. 2012. Methylhonokiol attenuates neuroinflammation: A role for cannabinoid receptors? Journal of Neuroinflammation 9: 135.
43. Giannakopoulos, P., F.R. Herrmann, T. Bussiere, C. Bouras, E. Kovari, D.P. Perl, J.H. Morrison, G. Gold, and P.R. Hof. 2003. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 60: 1495-1500.
44. Gold, M., C. Alderton, M. Zvartau-Hind, S. Egginton, A.M. Saunders, M. Irizarry, S. Craft, G. Landreth, U. Linnamagi, and S. Sawchak. 2010. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: Results from a randomized, double-blind, placebo-controlled phase III study. Dementia and Geriatric Cognitive Disorders 30: 131-146.
45. Goldeck, D., A. Larbi, M. Pellicano, I. Alam, I. Zerr, C. Schmidt, T. Fulop, and G. Pawelec. 2013. Enhanced chemokine receptor expression on leukocytes of patients with Alzheimer's disease. PLoS ONE 8: e66664.
46. Gonzalez, H., and R. Pacheco. 2014. T-cell-mediated regulation of neuroinflammation involved in neurodegenerative diseases. Journal of Neuroinflammation 11: 201.
47. Group, A.R., C.G. Lyketsos, J.C. Breitner, R.C. Green, B.K. Martin, C. Meinert, S. Piantadosi, and M. Sabbagh. 2007. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 68: 1800-1808.
48. Guedes, J., A.L. Cardoso, and M.C. Pedroso de Lima. 2013. Involvement of microRNA in microglia-mediated immune response. Clinical and Developmental Immunology 2013: 186872.
49. Guerreiro, R., A. Wojtas, J. Bras, M. Carrasquillo, E. Rogaeva, E. Majounie, C. Cruchaga, C. Sassi, J.S. Kauwe, S. Younkin, L. Hazrati, J. Collinge, J. Pocock, T. Lashley, J. Williams, J.C. Lambert, P. Amouyel, A. Goate, R. Rademakers, K. Morgan, J. Powell, P. St George-Hyslop, A. Singleton, and J. Hardy. 2013. TREM2 variants in Alzheimer's disease. New England Journal of Medicine 368: 117-127.
50. Hartlage-Rubsamen, M., U. Zeitschel, J. Apelt, U. Gartner, H. Franke, T. Stahl, A. Gunther, R. Schliebs, M. Penkowa, V. Bigl, and S. Rossner. 2003. Astrocytic expression of the Alzheimer's disease beta-secretase (BACE1) is stimulus-dependent. Glia 41: 169-179.
51. Hayden, K.M., P.P. Zandi, A.S. Khachaturian, C.A. Szekely, M. Fotuhi, M.C. Norton, J.T. Tschanz, C.F. Pieper, C. Corcoran, C.G. Lyketsos, J.C. Breitner, K.A. Welsh-Bohmer, and I. Cache County. 2007. Does NSAID use modify cognitive trajectories in the elderly? The Cache County study. Neurology 69: 275-282.
52. He, P., X. Cheng, M. Staufenbiel, R. Li, and Y. Shen. 2013. Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of beta-secretase in a mouse model of Alzheimer's disease. PLoS ONE 8: e55091.
53. Heneka, M.T., V. Gavrilyuk, G.E. Landreth, M.K. O'Banion, G. Weinberg, and D.L. Feinstein. 2003. Noradrenergic depletion increases inflammatory responses in brain: Effects on IkappaB and HSP70 expression. Journal of Neurochemistry 85: 387-398.
54. Heneka, M.T., G.E. Landreth, and D.L. Feinstein. 2001. Role for peroxisome proliferator-activated receptor-gamma in Alzheimer's disease. Annals of Neurology 49: 276.
55. Heneka, M.T., E. Reyes-Irisarri, M. Hull, and M.P. Kummer. 2011. Impact and Therapeutic Potential of PPARs in Alzheimer's Disease. Current Neuropharmacology 9: 643-650.
56. Heneka, M.T., M. Sastre, L. Dumitrescu-Ozimek, I. Dewachter, J. Walter, T. Klockgether, and F. Van Leuven. 2005a. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. Journal of Neuroinflammation 2: 22.
57. Heneka, M.T., M. Sastre, L. Dumitrescu-Ozimek, A. Hanke, I. Dewachter, C. Kuiperi, K. O'Banion, T. Klockgether, F. Van Leuven, and G.E. Landreth. 2005b. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128: 1442-1453.
58. Hickman, S.E., E.K. Allison, and J. El Khoury. 2008. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. Journal of Neuroscience 28: 8354-8360.
59. Howlett, A.C. 2005. Cannabinoid receptor signaling. Handbook of Experimental Pharmacology 168: 53-79.
60. Inestrosa, N.C., and E.M. Toledo. 2008. The role of Wnt signaling in neuronal dysfunction in Alzheimer's Disease. Molecular Neurodegeneration 3: 9.
61. Jahrling, J.B., C.M. Hernandez, L. Denner, and K.T. Dineley. 2014. PPARgamma recruitment to active ERK during memory consolidation is required for Alzheimer's disease-related cognitive enhancement. Journal of Neuroscience 34: 4054-4063.
62. Jaworski, T., B. Lechat, D. Demedts, L. Gielis, H. Devijver, P. Borghgraef, H. Duimel, F. Verheyen, S. Kugler, and F. Van Leuven. 2011. Dendritic degeneration, neurovascular defects, and inflammation precede neuronal loss in a mouse model for tau-mediated neurodegeneration. American Journal of Pathology 179: 2001-2015.
63. Jonsson, T., H. Stefansson, S. Steinberg, I. Jonsdottir, P.V. Jonsson, J. Snaedal, S. Bjornsson, J. Huttenlocher, A.I. Levey, J.J. Lah, D. Rujescu, H. Hampel, I. Giegling, O.A. Andreassen, K. Engedal, I. Ulstein, S. Djurovic, C. Ibrahim-Verbaas, A. Hofman, M.A. Ikram, C.M. van Duijn, U. Thorsteinsdottir, A. Kong, and K. Stefansson. 2013. Variant of TREM2 associated with the risk of Alzheimer's disease. New England Journal of Medicine 368: 107-116.
64. Kaufmann, W.E., K.I. Andreasson, P.C. Isakson, and P.F. Worley. 1997. Cyclooxygenases and the central nervous system. Prostaglandins 54: 601-624.
65. Kettenmann, H., U.K. Hanisch, M. Noda, and A. Verkhratsky. 2011. Physiology of microglia. Physiological Reviews 91: 461-553.
66. Kim, W.G., R.P. Mohney, B. Wilson, G.H. Jeohn, B. Liu, and J.S. Hong. 2000. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: Role of microglia. Journal of Neuroscience 20: 6309-6316.
67. Kitazawa, M., S. Oddo, T.R. Yamasaki, K.N. Green, and F.M. LaFerla. 2005. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. Journal of Neuroscience 25: 8843-8853.
68. Koenigsknecht-Talboo, J., and G.E. Landreth. 2005. Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. Journal of Neuroscience 25: 8240-8249.
69. Krishnan, S., R. Cairns, and R. Howard. 2009. Cannabinoids for the treatment of dementia. Cochrane Database of Systematic Reviews 15(2): CD007204.
70. Kukar, T., S. Prescott, J.L. Eriksen, V. Holloway, M.P. Murphy, E.H. Koo, T.E. Golde, and M.M. Nicolle. 2007. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neuroscience 8: 54.
71. Kummer, M.P., and M.T. Heneka. 2008. PPARs in Alzheimer's Disease. PPAR Research 2008: 403896.
72. Landreth, G.E., and M.T. Heneka. 2001. Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. Neurobiology of Aging 22: 937-944.
73. Laporte, V., G. Ait-Ghezala, C.H. Volmar, and M. Mullan. 2006. CD40 deficiency mitigates Alzheimer's disease pathology in transgenic mouse models. Journal of Neuroinflammation 3: 3.
74. Lee, Y.J., D.Y. Choi, I.S. Choi, K.H. Kim, Y.H. Kim, H.M. Kim, K. Lee, W.G. Cho, J.K. Jung, S.B. Han, J.Y. Han, S.Y. Nam, Y.W. Yun, J.H. Jeong, K.W. Oh, and J.T. Hong. 2012a. Inhibitory effect of 4-O-methylhonokiol on lipopolysaccharide-induced neuroinflammation, amyloidogenesis and memory impairment via inhibition of nuclear factor-kappaB in vitro and in vivo models. Journal of Neuroinflammation 9: 35.
75. Lee, Y.J., D.Y. Choi, Y.K. Lee, Y.M. Lee, S.B. Han, Y.H. Kim, K.H. Kim, S.Y. Nam, B.J. Lee, J.K. Kang, Y.W. Yun, K.W. Oh, and J.T. Hong. 2012b. 4-O-methylhonokiol prevents memory impairment in the Tg2576 transgenic mice model of Alzheimer's disease via regulation of beta-secretase activity. Journal of Alzheimer's Disease 29: 677-690.
76. Lee, Y.J., I.S. Choi, M.H. Park, Y.M. Lee, J.K. Song, Y.H. Kim, K.H. Kim, D.Y. Hwang, J.H. Jeong, Y.P. Yun, K.W. Oh, J.K. Jung, S.B. Han, and J.T. Hong. 2011a. 4-O-Methylhonokiol attenuates memory impairment in presenilin 2 mutant mice through reduction of oxidative damage and inactivation of astrocytes and the ERK pathway. Free Radical Biology and Medicine 50: 66-77.
77. Lee, Y.J., S.B. Han, S.Y. Nam, K.W. Oh, and J.T. Hong. 2010. Inflammation and Alzheimer's disease. Archives of Pharmacal Research 33: 1539-1556.
78. Lee, Y.J., Y.M. Lee, C.K. Lee, J.K. Jung, S.B. Han, and J.T. Hong. 2011b. Therapeutic applications of compounds in the Magnolia family. Pharmacology & Therapeutics 130: 157-176.
79. Leuner, K., S. Hauptmann, R. Abdel-Kader, I. Scherping, U. Keil, J.B. Strosznajder, A. Eckert, and W.E. Muller. 2007. Mitochondrial dysfunction: The first domino in brain aging and Alzheimer's disease? Antioxidants & Redox Signaling 9: 1659-1675.
80. Li, Y.Y., J.G. Cui, J.M. Hill, S. Bhattacharjee, Y. Zhao, and W.J. Lukiw. 2011. Increased expression of miRNA-146a in Alzheimer's disease transgenic mouse models. Neuroscience Letters 487: 94-98.
81. Liang, X., Q. Wang, T. Hand, L. Wu, R.M. Breyer, T.J. Montine, and K. Andreasson. 2005. Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. Journal of Neuroscience 25: 10180-10187.
82. Lim, D., A. Iyer, V. Ronco, A.A. Grolla, P.L. Canonico, E. Aronica, and A.A. Genazzani. 2013. Amyloid beta deregulates astroglial mGluR5-mediated calcium signaling via calcineurin and Nf-kB. Glia 61: 1134-1145.
83. Lim, G.P., F. Yang, T. Chu, E. Gahtan, O. Ubeda, W. Beech, J.B. Overmier, K. Hsiao-Ashec, S.A. Frautschy, and G.M. Cole. 2001. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiology of Aging 22: 983-991.
84. Liu, Q., H.G. Lee, K. Honda, S.L. Siedlak, P.L. Harris, A.D. Cash, X. Zhu, J. Avila, A. Nunomura, A. Takeda, M.A. Smith, and G. Perry. 2005. Tau modifiers as therapeutic targets for Alzheimer's disease. Biochimica et Biophysica Acta 1739: 211-215.
85. Liu, Y.J., D.W. Guo, L. Tian, D.S. Shang, W.D. Zhao, B. Li, W.G. Fang, L. Zhu, and Y.H. Chen. 2010. Peripheral T cells derived from Alzheimer's disease patients overexpress CXCR2 contributing to its transendothelial migration, which is microglial TNF-alpha-dependent. Neurobiology of Aging 31: 175-188.
86. Lukiw, W.J. 2007. Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus. NeuroReport 18: 297-300.
87. Lukiw, W.J., Y. Zhao, and J.G. Cui. 2008. An NF-kappaB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. Journal of Biological Chemistry 283: 31315-31322.
88. Mandrekar-Colucci, S., and G.E. Landreth. 2010. Microglia and inflammation in Alzheimer's disease. CNS & Neurological Disorders: Drug Targets 9: 156-167.
89. Mandrekar-Colucci, S., and G.E. Landreth. 2011. Nuclear receptors as therapeutic targets for Alzheimer's disease. Expert Opinion on Therapeutic Targets 15: 1085-1097.
90. Mandrekar-Colucci, S., A. Sauerbeck, P.G. Popovich, and D.M. McTigue. 2013. PPAR agonists as therapeutics for CNS trauma and neurological diseases. American Society for Neurochemistry 5: e00129.
91. Marsicano, G., S. Goodenough, K. Monory, H. Hermann, M. Eder, A. Cannich, S.C. Azad, M.G. Cascio, S.O. Gutierrez, M. van der Stelt, M.L. Lopez-Rodriguez, E. Casanova, G. Schutz, W. Zieglgansberger, V. Di Marzo, C. Behl, and B. Lutz. 2003. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302: 84-88.
92. Martin-Moreno, A.M., B. Brera, C. Spuch, E. Carro, L. Garcia-Garcia, M. Delgado, M.A. Pozo, N.G. Innamorato, A. Cuadrado, and M.L. de Ceballos. 2012. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in Tg APP 2576 mice. Journal of Neuroinflammation 9: 8.
93. Martin-Moreno, A.M., D. Reigada, B.G. Ramirez, R. Mechoulam, N. Innamorato, A. Cuadrado, and M.L. de Ceballos. 2011. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: Relevance to Alzheimer's disease. Molecular Pharmacology 79: 964-973.
94. Matsuoka, Y., M. Picciano, B. Malester, J. LaFrancois, C. Zehr, J.M. Daeschner, J.A. Olschowka, M.I. Fonseca, M.K. O'Banion, A.J. Tenner, C.A. Lemere, and K. Duff. 2001. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. American Journal of Pathology 158: 1345-1354.
95. McGeer, P.L., and E.G. McGeer. 2013. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: Implications for therapy. Acta Neuropathologica 126: 479-497.
96. McKee, A.C., I. Carreras, L. Hossain, H. Ryu, W.L. Klein, S. Oddo, F.M. LaFerla, B.G. Jenkins, N.W. Kowall, and A. Dedeoglu. 2008. Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Research 1207: 225-236.
97. Miller, B.W., K.C. Willett, and A.R. Desilets. 2011. Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease. Annals of Pharmacotherapy 45: 1416-1424.
98. Monsonego, A., J. Imitola, S. Petrovic, V. Zota, A. Nemirovsky, R. Baron, Y. Fisher, T. Owens, and H.L. Weiner. 2006. Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. Proceedings of the National Academy of Sciences USA 103: 5048-5053.
99. Monsonego, A., V. Zota, A. Karni, J.I. Krieger, A. Bar-Or, G. Bitan, A.E. Budson, R. Sperling, D.J. Selkoe, and H.L. Weiner. 2003. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. Journal of Clinical Investigation 112: 415-422.
100. Morales, I., L. Guzman-Martinez, C. Cerda-Troncoso, G.A. Farias, and R.B. Maccioni. 2014. Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel therapeutic approaches. Frontiers in Cellular Neuroscience 8: 112.
101. More, S.V., J.Y. Park, B.W. Kim, H. Kumar, H.W. Lim, S.M. Kang, S. Koppula, S.H. Yoon, and D.K. Choi. 2013. Anti-neuroinflammatory activity of a novel cannabinoid derivative by inhibiting the NF-kappaB signaling pathway in lipopolysaccharide-induced BV-2 microglial cells. Journal of Pharmaceutical Sciences 121: 119-130.
102. Mori, T., N. Koyama, G.W. Arendash, Y. Horikoshi-Sakuraba, J. Tan, and T. Town. 2010. Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease. Glia 58: 300-314.
103. Mucke, L., G.Q. Yu, L. McConlogue, E.M. Rockenstein, C.R. Abraham, and E. Masliah. 2000. Astroglial expression of human alpha(1)-antichymotrypsin enhances alzheimer-like pathology in amyloid protein precursor transgenic mice. American Journal of Pathology 157: 2003-2010.
104. Nagele, R.G., J. Wegiel, V. Venkataraman, H. Imaki, K.C. Wang, and J. Wegiel. 2004. Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease. Neurobiology of Aging 25: 663-674.
105. Netland, E.E., J.L. Newton, R.E. Majocha, and B.A. Tate. 1998. Indomethacin reverses the microglial response to amyloid beta-protein. Neurobiology of Aging 19: 201-204.
106. Nicolakakis, N., and E. Hamel. 2010. The nuclear receptor PPARgamma as a therapeutic target for cerebrovascular and brain dysfunction in Alzheimer's disease. Frontiers in Aging Neuroscience 2: 21.
107. Nilsson, L.N., K.R. Bales, G. DiCarlo, M.N. Gordon, D. Morgan, S.M. Paul, and H. Potter. 2001. Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease. Journal of Neuroscience 21: 1444-1451.
108. Ock, J., H.S. Han, S.H. Hong, S.Y. Lee, Y.M. Han, B.M. Kwon, and K. Suk. 2010. Obovatol attenuates microglia-mediated neuroinflammation by modulating redox regulation. British Journal of Pharmacology 159: 1646-1662.
109. Olivieri, F., M.R. Rippo, A.D. Procopio, and F. Fazioli. 2013. Circulating inflamma-miRs in aging and age-related diseases. Frontiers in Genetics 4: 121.
110. Ousman, S.S., and P. Kubes. 2012. Immune surveillance in the central nervous system. Nature Neuroscience 15: 1096-1101.
111. Padmanabhan, J., M. Levy, D.W. Dickson, and H. Potter. 2006. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons. Brain 129: 3020-3034.
112. Panza, F., V. Frisardi, V. Solfrizzi, B.P. Imbimbo, G. Logroscino, A. Santamato, A. Greco, D. Seripa, and A. Pilotto. 2012. Immunotherapy for Alzheimer's disease: From anti-beta-amyloid to tau-based immunization strategies. Immunotherapy 4: 213-238.
113. Pasqualetti, P., C. Bonomini, G. Dal Forno, L. Paulon, E. Sinforiani, C. Marra, O. Zanetti, and P.M. Rossini. 2009. A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease. Aging Clinical and Experimental Research 21: 102-110.
114. Passmore, M.J. 2008. The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation. International Journal of Geriatric Psychiatry 23: 116-117.
115. Prosperi, C., C. Scali, M. Barba, A. Bellucci, M.G. Giovannini, G. Pepeu, and F. Casamenti. 2004. Comparison between flurbiprofen and its nitric oxide-releasing derivatives HCT-1026 and NCX-2216 on Abeta(1-42)-induced brain inflammation and neuronal damage in the rat. International Journal of Immunopathology and Pharmacology 17: 317-330.
116. Qiao, X., D.J. Cummins, and S.M. Paul. 2001. Neuroinflammation-induced acceleration of amyloid deposition in the APPV717F transgenic mouse. European Journal of Neuroscience 14: 474-482.
117. Ransohoff, R.M., and B. Engelhardt. 2012. The anatomical and cellular basis of immune surveillance in the central nervous system. Nature Reviews Immunology 12: 623-635.
118. Ribizzi, G., S. Fiordoro, S. Barocci, E. Ferrari, and M. Megna. 2010. Cytokine polymorphisms and Alzheimer disease: Possible associations. Neurological Sciences 31: 321-325.
119. Risner, M.E., A.M. Saunders, J.F. Altman, G.C. Ormandy, S. Craft, I.M. Foley, M.E. Zvartau-Hind, D.A. Hosford, and A.D. Roses. 2006. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics Journal 6: 246-254.
120. Rogers, J., L.C. Kirby, S.R. Hempelman, D.L. Berry, P.L. McGeer, A.W. Kaszniak, J. Zalinski, M. Cofield, L. Mansukhani, P. Willson, et al. 1993. Clinical trial of indomethacin in Alzheimer's disease. Neurology 43: 1609-1611.
121. Ronco, A.M., M. Llanos, D. Tamayo, and S. Hirsch. 2007. Anandamide inhibits endothelin-1 production by human cultured endothelial cells: A new vascular action of this endocannabinoid. Pharmacology 79: 12-16.
122. Rossner, S., J. Apelt, R. Schliebs, J.R. Perez-Polo, and V. Bigl. 2001. Neuronal and glial beta-secretase (BACE) protein expression in transgenic Tg2576 mice with amyloid plaque pathology. Journal of Neuroscience Research 64: 437-446.
123. Rossner, S., C. Lange-Dohna, U. Zeitschel, and J.R. Perez-Polo. 2005. Alzheimer's disease beta-secretase BACE1 is not a neuron-specific enzyme. Journal of Neurochemistry 92: 226-234.
124. Sastre, M., I. Dewachter, G.E. Landreth, T.M. Willson, T. Klockgether, F. van Leuven, and M.T. Heneka. 2003. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. Journal of Neuroscience 23: 9796-9804.
125. Sastre, M., T. Klockgether, and M.T. Heneka. 2006. Contribution of inflammatory processes to Alzheimer's disease: Molecular mechanisms. International Journal of Developmental Neuroscience 24: 167-176.
126. Sato, T., H. Hanyu, K. Hirao, H. Kanetaka, H. Sakurai, and T. Iwamoto. 2011. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiology of Aging 32: 1626-1633.
127. Schuehly, W., J.M. Paredes, J. Kleyer, A. Huefner, S. Anavi-Goffer, S. Raduner, K.H. Altmann, and J. Gertsch. 2011. Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB(2) receptor inverse agonists. Chemistry & Biology 18: 1053-1064.
128. Searcy, J.L., J.T. Phelps, T. Pancani, I. Kadish, J. Popovic, K.L. Anderson, T.L. Beckett, M.P. Murphy, K.C. Chen, E.M. Blalock, P.W. Landfield, N.M. Porter, and O. Thibault. 2012. Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease. Journal of Alzheimer's Disease 30: 943-961.
129. Sethi, P., and W.J. Lukiw. 2009. Micro-RNA abundance and stability in human brain: Specific alterations in Alzheimer's disease temporal lobe neocortex. Neuroscience Letters 459: 100-104.
130. Shi, J.Q., W. Shen, J. Chen, B.R. Wang, L.L. Zhong, Y.W. Zhu, H.Q. Zhu, Q.Q. Zhang, Y.D. Zhang, and J. Xu. 2011a. Anti-TNF-alpha reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain Research 1368: 239-247.
131. Shi, J.Q., B.R. Wang, W.W. Jiang, J. Chen, Y.W. Zhu, L.L. Zhong, Y.D. Zhang, and J. Xu. 2011b. Cognitive improvement with intrathecal administration of infliximab in a woman with Alzheimer's disease. Journal of the American Geriatrics Society 59: 1142-1144.
132. Simpson, J.E., P.G. Ince, G. Lace, G. Forster, P.J. Shaw, F. Matthews, G. Savva, C. Brayne, and S.B. Wharton. 2010. Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain. Neurobiology of Aging 31: 578-590.
133. Sodhi, R.K., N. Singh, and A.S. Jaggi. 2011. Neuroprotective mechanisms of peroxisome proliferator-activated receptor agonists in Alzheimer's disease. Naunyn-Schmiedeberg's Archives of Pharmacology 384: 115-124.
134. Soininen, H., C. West, J. Robbins, and L. Niculescu. 2007. Long-term efficacy and safety of celecoxib in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 23: 8-21.
135. Solas, M., P.T. Francis, R. Franco, and M.J. Ramirez. 2013. CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients. Neurobiology of Aging 34: 805-808.
136. Solito, E., and M. Sastre. 2012. Microglia function in Alzheimer's disease. Frontiers in Pharmacology 3: 14.
137. Steele, M.L., and S.R. Robinson. 2012. Reactive astrocytes give neurons less support: Implications for Alzheimer's disease. Neurobiology of Aging 33: e1-e13.
138. Stewart, W.F., C. Kawas, M. Corrada, and E.J. Metter. 1997. Risk of Alzheimer's disease and duration of NSAID use. Neurology 48: 626-632.
139. Stumm, C., C. Hiebel, R. Hanstein, M. Purrio, H. Nagel, A. Conrad, B. Lutz, C. Behl, and A.B. Clement. 2013. Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer's disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition. Neurobiology of Aging 34: 2574-2584.
140. Sung, S., H. Yang, K. Uryu, E.B. Lee, L. Zhao, D. Shineman, J.Q. Trojanowski, V.M. Lee, and D. Pratico. 2004. Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease. American Journal of Pathology 165: 2197-2206.
141. Sy, M., M. Kitazawa, R. Medeiros, L. Whitman, D. Cheng, T.E. Lane, and F.M. Laferla. 2011. Inflammation induced by infection potentiates tau pathological features in transgenic mice. American Journal of Pathology 178: 2811-2822.
142. Szekely, C.A., J.C. Breitner, A.L. Fitzpatrick, T.D. Rea, B.M. Psaty, Z.H. Kuller, and P.P. Zandi. 2008. NSAID use and dementia risk in the Cardiovascular Health Study: Role of APOE and NSAID type. Neurology 70: 17-24.
143. Thal, L.J., S.H. Ferris, L. Kirby, G.A. Block, C.R. Lines, E. Yuen, C. Assaid, M.L. Nessly, B.A. Norman, C.C. Baranak, and S.A. Reines. 2005. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 30: 1204-1215.
144. Thounaojam, M.C., D.K. Kaushik, and A. Basu. 2013. MicroRNAs in the brain: It's regulatory role in neuroinflammation. Molecular Neurobiology 47: 1034-1044.
145. Tobinick, E., H. Gross, A. Weinberger, and H. Cohen. 2006. TNF-alpha modulation for treatment of Alzheimer's disease: A 6-month pilot study. Medscape General Medicine 8: 25.
146. Tobinick, E.L., and H. Gross. 2008. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. Journal of Neuroinflammation 5: 2.
147. Togo, T., H. Akiyama, E. Iseki, H. Kondo, K. Ikeda, M. Kato, T. Oda, K. Tsuchiya, and K. Kosaka. 2002. Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases. Journal of Neuroimmunology 124: 83-92.
148. Townsend, K.P., T. Town, T. Mori, L.F. Lue, D. Shytle, P.R. Sanberg, D. Morgan, F. Fernandez, R.A. Flavell, and J. Tan. 2005. CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid beta-peptide. European Journal of Immunology 35: 901-910.
149. Trepanier, C.H., and N.W. Milgram. 2010. Neuroinflammation in Alzheimer's disease: Are NSAIDs and selective COX-2 inhibitors the next line of therapy? Journal of Alzheimer's Disease 21: 1089-1099.
150. Verkhratsky, A., M. Olabarria, H.N. Noristani, C.Y. Yeh, and J.J. Rodriguez. 2010. Astrocytes in Alzheimer's disease. Neurotherapeutics 7: 399-412.
151. Vitek, M.P., C.M. Brown, and C.A. Colton. 2009. APOE genotype-specific differences in the innate immune response. Neurobiology of Aging 30: 1350-1360.
152. Volicer, L., M. Stelly, J. Morris, J. McLaughlin, and B.J. Volicer. 1997. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry 12: 913-919.
153. Walther, S., R. Mahlberg, U. Eichmann, and D. Kunz. 2006. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology (Berl) 185: 524-528.
154. Walther, S., B. Schupbach, E. Seifritz, P. Homan, and W. Strik. 2011. Randomized, controlled crossover trial of dronabinol, 2.5 mg, for agitation in 2 patients with dementia. Journal of Clinical Psychopharmacology 31: 256-258.
155. Watson, G.S., B.A. Cholerton, M.A. Reger, L.D. Baker, S.R. Plymate, S. Asthana, M.A. Fishel, J.J. Kulstad, P.S. Green, D.G. Cook, S.E. Kahn, M.L. Keeling, and S. Craft. 2005. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: A preliminary study. The American Journal of Geriatric Psychiatry 13: 950-958.
156. Weggen, S., J.L. Eriksen, S.A. Sagi, C.U. Pietrzik, V. Ozols, A. Fauq, T.E. Golde, and E.H. Koo. 2003. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. Journal of Biological Chemistry 278: 31831-31837.
157. Wenk, G.L. 2003. Neuropathologic changes in Alzheimer's disease. Journal of Clinical Psychiatry 64: 7-10.
158. Yan, Q., J. Zhang, H. Liu, S. Babu-Khan, R. Vassar, A.L. Biere, M. Citron, and G. Landreth. 2003. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. Journal of Neuroscience 23: 7504-7509.
159. Yoshiyama, Y., M. Higuchi, B. Zhang, S.M. Huang, N. Iwata, T.C. Saido, J. Maeda, T. Suhara, J.Q. Trojanowski, and V.M. Lee. 2007. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53: 337-351.
160. Zahs, K.R., and K.H. Ashe. 2010. 'Too much good news' - Are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? Trends in Neurosciences 33: 381-389.
161. Zhao, Y., S. Bhattacharjee, B.M. Jones, P. Dua, P.N. Alexandrov, J.M. Hill, and W.J. Lukiw. 2013. Regulation of TREM2 expression by an NF-small ka, CyrillicB-sensitive miRNA-34a. NeuroReport 24: 318-323.